nach oben

Current Atherosclerosis Reports

Erschienen in:

06.06.2022 | Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know

verfasst von: Johnathon Seth Parham, Anne Carol Goldberg

Erschienen in: Current Atherosclerosis Reports | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

There have been recent developments of novel therapeutic agents for lipid lowering. This article reviews treatment concepts for two of the newest lipid-lowering medications.

Recent Findings

Bempedoic acid inhibits adenosine citrate lyase, decreasing intracellular lipogenesis. This oral medication is a prodrug and requires activation by enzymes present in hepatocytes but absent in the skeletal muscle. Clinical trials demonstrated additive benefit with statin therapy, and it was well tolerated in statin-intolerant populations. Inclisiran uses RNA interference to prevent translation of PCSK9 mRNA. Due to its stability, it can be given as an injection every 6 months and produces consistent, durable, and potent cholesterol lowering.

Summary

Bempedoic acid and inclisiran represent new avenues of treatment for the prevention and treatment of cardiovascular disease. This will allow for more comprehensive care by addressing challenges with medication adherence, such as adverse effects to prior medications as well as ease of dosing.

Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–492.PubMedCrossRef

Nelson S, Whitsel L, Khavjou O, Phelps D, Leib A. Projections of cardiovascular disease prevalence and costs: 2015–2035. RTI International. Published November 2016. Available at: https://healthmetrics.heart.org/wp-content/uploads/2017/10/Projections-of-Cardiovascular-Disease.pdf. Accessed October 29^th 2021.

Joshi PH, Martin SS, Blumenthal RS. The remnants of residual risk. J Am Coll Cardiol. 2015;65:2276–8.PubMedCrossRef

Ray KK, Molemans B, Schoonen WM, et al. DA VINCI study. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89.PubMedCrossRef

Miedema MD, Virani SS. Harder-to-treat patients: recognizing them and adapting treatment strategies. Am J Cardiol. 2016;118:13A-18A.PubMedCrossRef

Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40:243–54.PubMedPubMedCentralCrossRef

Berkhout TA, Havekes LM, Pearce NJ, Groot PH. The effect of (-)- hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J. 1990;272:181–6.PubMedPubMedCentralCrossRef

Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161–72.PubMedPubMedCentralCrossRef

Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.PubMedPubMedCentralCrossRef

10.

A multiple ascending dose study of ETC-1002 in healthy subjects; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT01485146. Accessed October 22, 2021.

11.

A multiple ascending dose study of ETC-1002 in subjects with mild dyslipidemia; 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT01105598. Accessed October 22, 2021.

12.

Single radiolabeled dose study to investigate the absorption, metabolism and excretion of [14C]-ETC-1002. Available from: https://clinicaltrials.gov/ct2/show/NCT02044627. Accessed October 22, 2021.

13.

Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterollowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34:676–83.PubMedCrossRef

14.

Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295–304.PubMedCrossRef

15.

Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10:556–67.PubMedCrossRef

16.

Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154–62.PubMedCrossRef

17.

A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01779453. Accessed October 22, 2021.

18.

Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. Available from: https://clinicaltrials.gov/ct2/show/NCT02178098. Accessed October 22, 2021.

19.

Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT03193047. Accessed October 22, 2021.

20.

Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20 mg triplet therapy in patients with elevated LDL-C. Available from: https://clinicaltrials.gov/ct2/show/NCT03051100. Accessed October 22, 2021.

21.

Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13:568–79.PubMedCrossRef

22.•

Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32. Phase III trial.PubMedCrossRef

23.•

Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322:1780–1788. Phase III trial.

24.

NEXLETOL prescribing information. https://pi.esperion.com/NEXLETOL. Accessed February 11, 2022.)

25.••

Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603. Trial resulted in FDA approval of combination bempedoic acid-ezetimibe.PubMedCrossRef

26.

Duell PB, Banach M, Catapano AL, Laufs U, Mancini GBJ, Ray KK, Bloedon LT, Ye Z, Goldberg AC. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials. Atherosclerosis. 2020;315:e12–3.CrossRef

27.•

Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8: e011662. Demonstrated safety in statin intolerance population.PubMedPubMedCentralCrossRef

28.

Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther. 2021;15:1955–63.PubMedPubMedCentralCrossRef

29.

Banach M, Duell PB, Gotto AM, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5:1124.PubMedCrossRef

30.

Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.PubMedCrossRef

31.

Nicholls SJ, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104–12.PubMedCrossRef

32.

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.PubMedCrossRef

33.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.CrossRef

34.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505.PubMedCrossRef

35.

Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–53.PubMedCrossRef

36.

Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol–lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316:1383–91.PubMedPubMedCentralCrossRef

37.

Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380:1033–42.PubMedPubMedCentralCrossRef

38.

Cicero AFG, Fogacci F, Hernandez AV, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17:e1003121.PubMedPubMedCentralCrossRef

39.

Csanadi A, Kayser C, Donauer M, Gumpp V, Aumann K, Rawluk J, Prasse A, ZurHausen A, Wiesemann S, Werner M, Kayser G. Prognostic value of malic enzyme and ATP-citrate lyase in non-small cell lung cancer of the young and the elderly. PLoS One. 2015;10:e0126357.PubMedPubMedCentralCrossRef

40.

Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther. 2013;12:2782–91.PubMedPubMedCentralCrossRef

41.

Wang D, Yin L, Wei J, Yang Z, Jiang G. ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis. Tumour Biol. 2017;39:1010428317698338.PubMed

42.

Granchi C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157:1276–91.PubMedCrossRef

43.

Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125–34.PubMedCrossRef

44.

Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol. 2012;227:1709–20.PubMedPubMedCentralCrossRef

45.

Hannon G. RNA interference. Nature. 2002;418:244–51.PubMedCrossRef

46.

Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 2018;14:433–42.PubMedCrossRef

47.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41–51.PubMedCrossRef

48.

Ray KK. Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1. Paper presented at: European Society of Cardiology (ESC) Congress 2017(August), pp. 26–30. Barcelona. Spain: FP Number; 2017. p. 3064.

49.

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP. ORION-10 and ORION-11 Investigators Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19 Phase III trial..PubMedCrossRef

50.

Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP. ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–30 Phase III trial..PubMedCrossRef

51.

Wright RS, Ray KK, Raal FJ, et al. ORION Phase III Investigators. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182–93.PubMedCrossRef

52.

Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.PubMedPubMedCentralCrossRef

53.

Feske SK. A new treatable risk factor for stroke and atherosclerotic cardiovascular disease? J Am Coll Cardiol. 2017;69:159–61.PubMedCrossRef

54.

A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). Available from: https://clinicaltrials.gov/ct2/show/NCT03705234. Accessed October 29^th 2021.

55.

A study of inclisiran in participants with homozygous familial hypercholesterolemia (HoFH) (ORION-5). Available from: https://clinicaltrials.gov/ct2/show/NCT03851705. Accessed October 29^th 2021.

56.

FDA approves add-on therapy to lower cholesterol among certain high-risk adults. Food and Drug Administration Web site. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults. Accessed January 25^th 2022.

57.

LEQVIO prescribing information. Leqviohcp.com. Accessed February 11, 2022.

58.

Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.PubMedCrossRef

Titel: Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
verfasst von: Johnathon Seth Parham
Anne Carol Goldberg
Publikationsdatum: 06.06.2022
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 8/2022
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-022-01036-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave

Statins in Pregnancy: Can We Justify Early Treatment of Reproductive Aged Women?

Bioactives in the Food Supply: Effects on CVD Health

Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions